Semin intervent Radiol 2021; 38(04): 412-418
DOI: 10.1055/s-0041-1733903
Review Article

Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data

Janesh Lakhoo
1   Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee
,
Thomas H. Perez
1   Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee
,
Anthony J. Borgmann
1   Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee
,
Daniel B. Brown
1   Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee
› Author Affiliations

Abstract

Historically, outcomes reporting for radioembolization with yttrium-90 (90Y) of hepatocellular carcinoma has included patients across the range of Barcelona Clinic Liver Cancer (BCLC) stages. With the potential for curative radiation segmentectomy for BCLC 0/A patients and evolution of systemic therapy for BCLC C patients, focused review by group is of increasing interest. In this review, we report on efficacy of 90Y in patients with intermediate (BCLC B) and advanced (BCLC C) hepatocellular carcinoma as well as expected toxicities. Additionally, we review existing trials comparing 90Y to transarterial chemoembolization and systemic treatments in these patient groups and outline future studies.



Publication History

Article published online:
07 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019; 380 (15) 1450-1462
  • 2 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391 (10127): 1301-1314
  • 3 Salem R, Miller FH, Yaghmai V, Lewandowski RJ. Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments. J Hepatol 2013; 58 (06) 1260-1262
  • 4 Salem R, Gilbertsen M, Butt Z. et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11 (10) 1358-1365.e1
  • 5 Salem R, Gabr A, Riaz A. et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018; 68 (04) 1429-1440
  • 6 Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol 2017; 8 (05) 799-807
  • 7 Ali R, Gabr A, Abouchaleh N. et al. Survival analysis of advanced HCC treated with radioembolization: comparing impact of clinical performance status versus vascular invasion/metastases. Cardiovasc Intervent Radiol 2018; 41 (02) 260-269
  • 8 Frantz S, Matsuoka L, Vaheesan K. et al. Multi-center evaluation of survival and toxicities following radioembolization of hepatocellular carcinoma: analysis of the RESiN Registry. J Vasc Interv Radiol 2021; 32 (06) 845-852
  • 9 Mazzaferro V, Sposito C, Bhoori S. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57 (05) 1826-1837
  • 10 Allimant C, Kafrouni M, Delicque J. et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol 2018; 29 (12) 1662-1670.e4
  • 11 Garin E, Tselikas L, Guiu B. et al; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29
  • 12 Salem R, Gordon AC, Mouli S. et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
  • 13 Salem R, Lewandowski RJ, Kulik L. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140 (02) 497-507.e2
  • 14 Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends 2015; 9 (05) 289-298
  • 15 Vilgrain V, Pereira H, Assenat E. et al; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (12) 1624-1636
  • 16 Chow PKH, Gandhi M, Tan SB. et al; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018; 36 (19) 1913-1921
  • 17 Ricke J, Bulla K, Kolligs F. et al; SORAMIC Study Group. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int 2015; 35 (02) 620-626
  • 18 Javan H, Dayyani F, Abi-Jaoudeh N. Therapy in advanced hepatocellular carcinoma. Semin Intervent Radiol 2020; 37 (05) 466-474
  • 19 Zhan C, Ruohoniemi D, Shanbhogue KP. et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol 2020; 31 (01) 25-34
  • 20 El-Khoueiry AB, Sangro B, Yau T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389 (10088): 2492-2502
  • 21 Zhu AX, Finn RS, Edeline J. et al; KEYNOTE-224 Investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19 (07) 940-952
  • 22 Brown D, Krebs H, Brower J. et al. Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry. J Gastrointest Oncol 2021; 12 (02) 639-657
  • 23 Golfieri R, Bilbao JI, Carpanese L. et al; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol 2013; 59 (04) 753-761
  • 24 Iñarrairaegui M, Thurston KG, Bilbao JI. et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21 (08) 1205-1212
  • 25 Kulik LM, Carr BI, Mulcahy MF. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47 (01) 71-81
  • 26 Zimmermann M, Schulze-Hagen M, Liebl M. et al. Safety and efficacy of y-90 radioembolization after prior major hepatic resection. Cardiovasc Intervent Radiol 2017; 40 (08) 1206-1212
  • 27 Emami B, Lyman J, Brown A. et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21 (01) 109-122
  • 28 Das A, Riaz A, Gabr A. et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging 2020; 47 (04) 807-815
  • 29 Seidensticker R, Seidensticker M, Damm R. et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 2012; 35 (05) 1109-1118